Wei‐Chi Liao

487 total citations
31 papers, 355 citations indexed

About

Wei‐Chi Liao is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Wei‐Chi Liao has authored 31 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cardiology and Cardiovascular Medicine, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Wei‐Chi Liao's work include Heart Failure Treatment and Management (8 papers), Blood Pressure and Hypertension Studies (6 papers) and Renin-Angiotensin System Studies (6 papers). Wei‐Chi Liao is often cited by papers focused on Heart Failure Treatment and Management (8 papers), Blood Pressure and Hypertension Studies (6 papers) and Renin-Angiotensin System Studies (6 papers). Wei‐Chi Liao collaborates with scholars based in United States, Germany and Taiwan. Wei‐Chi Liao's co-authors include O. Vesterqvist, Michael Ruddy, Clarence E. Grim, Carlos M. Ferrario, Ronald D. Smith, Peter Trenkwalder, Chengyi Tu, Sheng‐Nan Chang, Thomas Littlejohn and Cheng‐Li Lin and has published in prestigious journals such as Hypertension, IEEE Transactions on Electron Devices and Clinical Pharmacology & Therapeutics.

In The Last Decade

Wei‐Chi Liao

28 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wei‐Chi Liao United States 10 229 108 69 42 37 31 355
Henry Yu United States 6 259 1.1× 111 1.0× 38 0.6× 7 0.2× 21 0.6× 8 478
Nobuyoshi Takagi Japan 12 156 0.7× 110 1.0× 33 0.5× 15 0.4× 57 1.5× 32 371
D Vasmant France 10 128 0.6× 66 0.6× 42 0.6× 17 0.4× 13 0.4× 44 328
A J Apperloo Netherlands 6 235 1.0× 144 1.3× 58 0.8× 27 0.6× 30 0.8× 7 419
Kerstin Tolagen Sweden 13 237 1.0× 126 1.2× 61 0.9× 11 0.3× 23 0.6× 20 387
Kazuhito Shiosakai Japan 15 151 0.7× 133 1.2× 65 0.9× 12 0.3× 43 1.2× 58 544
Martin P. Bedigian United States 9 480 2.1× 353 3.3× 19 0.3× 17 0.4× 44 1.2× 15 680
Konstantin Gurbanov Israel 9 213 0.9× 53 0.5× 74 1.1× 6 0.1× 14 0.4× 13 376
Heribert Schunkert Germany 14 403 1.8× 78 0.7× 41 0.6× 8 0.2× 19 0.5× 35 502
Norah S. Karlovich United States 5 96 0.4× 96 0.9× 25 0.4× 7 0.2× 31 0.8× 6 341

Countries citing papers authored by Wei‐Chi Liao

Since Specialization
Citations

This map shows the geographic impact of Wei‐Chi Liao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Chi Liao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Chi Liao more than expected).

Fields of papers citing papers by Wei‐Chi Liao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei‐Chi Liao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Chi Liao. The network helps show where Wei‐Chi Liao may publish in the future.

Co-authorship network of co-authors of Wei‐Chi Liao

This figure shows the co-authorship network connecting the top 25 collaborators of Wei‐Chi Liao. A scholar is included among the top collaborators of Wei‐Chi Liao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei‐Chi Liao. Wei‐Chi Liao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Chien-Chuan, Chu‐Kuang Chou, Jia‐Feng Wu, et al.. (2025). Effect of Anti-reflux Mucosal Ablation on Esophageal Motility in Patients With Gastroesophageal Reflux Disease: A Study Based on High-resolution Impedance Manometry. Journal of Neurogastroenterology and Motility. 31(1). 75–85. 3 indexed citations
2.
3.
Patel, Shanon, Wei‐Chi Liao, Matthew C. Davis, et al.. (2025). Position statement on longitudinal cracks and fractures of teeth. International Endodontic Journal. 58(3). 379–390. 4 indexed citations
4.
5.
Liao, Wei‐Chi & Jenn‐Gwo Hwu. (2024). Low Interface Trap Density 4H-SiC MIS Structure With SiO₂ Grown by Sub- 1000 °C Intermittent Spray Hydrated Oxidation (ISHO) for UV Sensor Applications. IEEE Transactions on Electron Devices. 71(12). 7787–7793. 1 indexed citations
6.
Tsai, Yi‐Ling, Wei‐Chi Liao, Chih‐Yuan Wang, et al.. (2016). Horizontal root fractures in posterior teeth without dental trauma: tooth/root distribution and clinical characteristics. International Endodontic Journal. 50(9). 830–835. 6 indexed citations
7.
Liao, Wei‐Chi, O. Vesterqvist, Carol Delaney, et al.. (2003). Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects. British Journal of Clinical Pharmacology. 56(4). 395–406. 18 indexed citations
8.
Kostis, John B., Randy Dockens, Udho Thadani, et al.. (2002). Comparison of Pharmacokinetics of Lanoteplase and Alteplase During Acute Myocardial Infarction. Clinical Pharmacokinetics. 41(6). 445–452. 11 indexed citations
9.
Ferrario, Carlos M., Ronald D. Smith, Mark C. Chappell, et al.. (2002). Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. American Journal of Hypertension. 15(6). 557–564. 55 indexed citations
10.
Malhotra, Bimal, Ramaswamy A. Iyer, Wei‐Chi Liao, et al.. (2001). Oral Bioavailability and Disposition of [14C]Omapatrilat in Healthy Subjects. The Journal of Clinical Pharmacology. 41(8). 833–841. 8 indexed citations
11.
Liao, Wei‐Chi, et al.. (2001). Effects of Age and Gender on the Pharmacodynamics of Omapatrilat in Healthy Volunteers. The American Journal of Geriatric Cardiology. 10(1). 50–54. 2 indexed citations
12.
Dong, Yafeng, et al.. (2001). The cardiovascular actions of omapatrilat in spontaneously hypertensive rats. Current Hypertension Reports. 3(S2). S1–S5. 5 indexed citations
13.
Kostis, John B., Marc Klapholz, O. Vesterqvist, et al.. (2001). Pharmacodynamics and Pharmacokinetics of Omapatrilat in Heart Failure. The Journal of Clinical Pharmacology. 41(12). 1280–1290. 9 indexed citations
14.
Uderman, Howard D., et al.. (2001). Omapatrilat: Neurohormonal and Pharmacodynamic Profile When Administered with Furosemide. The Journal of Clinical Pharmacology. 41(12). 1291–1300. 1 indexed citations
15.
Campese, Vito M., Kenneth C. Lasseter, Carlos M. Ferrario, et al.. (2001). Omapatrilat Versus Lisinopril. Hypertension. 38(6). 1342–1348. 50 indexed citations
16.
Greenbaum, R., et al.. (2000). Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. British Journal of Clinical Pharmacology. 49(1). 23–31. 36 indexed citations
17.
18.
Ding, Philip Yu An, Oliver Yoa‐Pu Hu, Audrey N. Chang, et al.. (1999). Fosinopril: Pharmacokinetics and Pharmacodynamics in Chinese Subjects. The Journal of Clinical Pharmacology. 39(2). 155–160. 6 indexed citations
19.
Chen, Hong, Philip Yu An Ding, Mau‐Song Chang, et al.. (1998). Pharmacokinetics of Fosinopril in Chinese Patients with Mild to Moderate Congestive Heart Failure. Clinical Drug Investigation. 16(5). 377–385. 1 indexed citations
20.
Kostis, John B., et al.. (1995). Fosinopril: Pharmacokinetics and pharmacodynamics in congestive heart failure*. Clinical Pharmacology & Therapeutics. 58(6). 660–665. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Henry Yu Breakdown of academic impact, for papers by Nobuyoshi Takagi Breakdown of academic impact, for papers by D Vasmant Breakdown of academic impact, for papers by A J Apperloo Breakdown of academic impact, for papers by Kerstin Tolagen Breakdown of academic impact, for papers by Kazuhito Shiosakai Breakdown of academic impact, for papers by Martin P. Bedigian Breakdown of academic impact, for papers by Konstantin Gurbanov Breakdown of academic impact, for papers by Heribert Schunkert Breakdown of academic impact, for papers by Norah S. Karlovich
Rankless by CCL
2026